Addressing metabolic changes early, before significant weight gain occurs, could prevent the cascade of complications that make later intervention more difficult
NICE recommended semaglutide 2.4 mg (TA875, 2023) for use within specialist Tier 3 weight management services in adults with a BMI of 35 kg/m (or 32.5 kg/m in people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background) with at least one weight-related comorbidity, or a BMI of 3034.9 kg/m in specific circumstances
Retatrutide may interest people who: are curious about next-generation metabolic therapies, want a broader metabolic approach, or are interested in therapies that may influence both appetite and energy expenditure
Originally developed for managing blood sugar levels, it has shown remarkable results in weight loss treatments as well
* Averages from clinical trials in controlled settings alongside diet and lifestyle support
Remember that what might be automatic in your home country (like informing regulators of SAEs, or providing documents in local language) needs equal attention in Korea
